Effects and management of denosumab discontinuation. [electronic resource]
Producer: 20191128Description: 515-517 p. digitalISSN:- 1778-7254
- Aged
- Bone Density Conservation Agents -- adverse effects
- Denosumab -- adverse effects
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Maximum Tolerated Dose
- Middle Aged
- Osteoporosis, Postmenopausal -- diagnosis
- Osteoporotic Fractures -- prevention & control
- Patient Safety
- Prognosis
- Retreatment
- Time Factors
- Withholding Treatment
No physical items for this record
Publication Type: Editorial; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.